BAYER AG /FI Form SC 13D/A October 14, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Pharmanetics, Inc.

-----

(Name of Issuer)

Common Stock

(Title of Class of Securities)

71713J107 (CUSIP Number)

Gregory Maloblocki, Esq.
Bayer Corporation
63 North Street
Medfield, MA
02052-1688

with a copy to:
Marilyn Mooney, Esq.
Fulbright & Jaworski L.L.P.
801 Pennsylvania Avenue, NW
Washington, D.C. 20004-2623

\_\_\_\_\_

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 10, 2003

-----

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the following box. [ ]

Note: Schedules filed in paper format shall include a signed original and five copies of this Schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act

but shall be subject to all other provisions of the  $\mbox{Act}$  (however, see the  $\mbox{Notes}$ ).

CUSIP No.	71713J107			Page 2 of 6 Pages		
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Bayer Corporation					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (a)      (b) [ ]					
3	SEC USE ONLY					
4	SOURCE OF FUNDS					
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)					
6 CITIZENSHIP OR PLACE OF ORGANIZATION Indiana						
		7	SOLE VOTING POWER 0			
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		8	SHARED VOTING POWER 2,050,000			
		9	SOLE DISPOSITIVE POWER 0			
		10	SHARED DISPOSITIVE POW. 2,050,000	ER		
11	AGGREGATE AMOUNT	BENEFICI.	ALLY OWNED BY EACH REPO	RTING PERSON		
	2,050,000					
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES SHARES					
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 20.9%					
14	TYPE OF REPORTING PERSON CO					
CUSIP No.	JSIP No. 71713J107 Page 3 of 6 Pages					
1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Bayer Aktiengesellshaft					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (a)      (b) [ ]					

3	SEC USE ONLY	SEC USE ONLY				
4	SOURCE OF FUNDS					
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)					
6	CITIZENSHIP OR PLACE OF ORGANIZATION Federal Republic of Germany					
	UMBER OF SHARES NEFICIALLY DWNED BY EACH EPORTING PERSON WITH	7	SOLE VOTING POWER 0			
BEI		8	SHARED VOTING POWER 2,050,000			
		9	SOLE DISPOSITIVE POWER 0			
		10	SHARED DISPOSITIVE POWER 2,050,000			
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,050,000					
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES SHARES					
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 20.9%					
14	TYPE OF REPORTING PERSON CO					
CUSIP No.	71713J107		Page 4 of 6 Pages			
1	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Bayer HealthCare LLC					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (a)      (b) [ ]					
3	SEC USE ONLY					
4	SOURCE OF FUNDS					
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)					
6	CITIZENSHIP OR P Delaware	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware				
	7 SOLE VOTING POWER					
NUMBER OF						

	SHARES EFICIALLY	8	SHARED VOTING POWER 2,050,000
OWNED BY			2,000,000
	EACH	9	SOLE DISPOSITIVE POWER
	PORTING		0
	PERSON WITH	10	SHARED DISPOSITIVE POWER 2,050,000
11	AGGREGATE AMOUNT	BENEFICIA	ALLY OWNED BY EACH REPORTING PERSON
	2,050,000		
12	CHECK BOX IF THE	AGGREGATI	E AMOUNT IN ROW (11) EXCLUDES SHARES
13	PERCENT OF CLASS 20.9%	REPRESENT	TED BY AMOUNT IN ROW (11)
14	TYPE OF REPORTING	G PERSON	

CUSIP No. 71713J107

Page 5 of 6 Pages

Item 4. Purpose of Transaction.

On October 10, 2003, Bayer Corporation's (the "Company") representative on the Issuer's board of directors resigned as a director. Pursuant to the Common Stock Purchase Agreement dated April 23, 2001 between the Company and the Issuer, as amended April 30, 2003 (the "Agreement"), the Company is entitled to designate a new nominee for election by the board of directors to serve until the immediately succeeding annual meeting of shareholders. The Company has advised the Issuer that it does not currently plan to make such a designation. Such a decision, however, does not constitute a waiver of the Company's rights to so designate in the future prior to the next meeting of shareholders at which directors will be elected, nor does it preclude the Company from exercising its rights under the Agreement to designate a director nominee in connection with the Issuer's next meeting of shareholders at which directors will be elected.

CUSIP No. 71713J107

Page 6 of 6 Pages

#### Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this amendment to this statement is true and correct.

Date: October 14, 2003 BAYER CORPORATION

By: /s/ Joseph A. Akers

\_\_\_\_\_

Joseph A. Akers

Executive Vice President,

Chief Administrative and Financial Officer

BAYER HEALTHCARE LLC

By: /s/ Frank Wenzel

\_\_\_\_\_

Frank Wenzel

Vice President, Biltroller and

Chief Accounting Officer

BAYER AKTIENGESELLSHAFT

By: /s/ Klaus Kuehn

\_\_\_\_\_

Klaus Kuehn

Member, Board of Management